CAR-T therapy breaks a pattern of stagnant efficacy growth in pharmaceutical innovation. A new CAR-T therapy study demonstrates significantly greater incremental effectiveness and similar cost–effectiveness to previous anticancer treatments.
In this on-demand webinar, a panel of Precision's top gene and cell therapy leaders tackles the challenge of how to demonstrate the short and long-term value of a therapy when clinical data is lacking.
This expert panel tackles head-on some of the hottest topics and trends in health economics and outcomes research today, and what you need to know to be successful in 2020.
Precision is excited to be headed to Copenhagen, November 2nd - 6th! Be sure to catch our scientific presentations at the conference, and meet our experts!
Adapted from Steve's recent presentations at the AMCP and ISPOR conferences, this on-demand webinar will provide an overview of value-based contracting and some of the key challenges to successful implementation.
Meet our subject matter experts to hear how we can support you with health technology assessments, new models for evidence synthesis, and defending the value of your treatments to payers.
In this unique one-hour webinar, Dr. Jena outlines a framework for assessing value to improve high-value treatments and identify low-value therapies on which spending can safely be reduced.
By limiting the benefits included in its model and inappropriately valuing these health benefits, ICER risks mispricing innovative health therapies and disincentivizing investments in research and development.
In this article, we explore critical factors in the development of gene therapies, including trial management, accelerated approval pathways, and companion diagnostic development and its coordination with therapeutic development.
Hear from globally recognized expert Dr. Jeroen Jansen on how to improve your evidence synthesis approaches to understand value, with applications to oncology.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
